Brickell reports no safety issues with flagship clinical product
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) said early data was positive for pivotal trials for its anti-excessive-sweating treatment, sending the stock up in after-hours trading.
The Boulder pharmaceutical company said a 12-month Phase III study of its flagship treatment sofpironium bromide produced no adverse effects in 300 patients.
“As we continue to prepare for the initiation of our pivotal studies, we are encouraged by the top-line results of our recently completed Phase 3 long-term safety study,” CEO Robert Brown said in a statement.
Earlier this month, Brickell and its development partner Kaken Pharmaceutical Co.…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Boulder-based publishing technology company Sovrn Holdings Inc. has named Will Duckworth its chief technology officer.
-
A Boulder fiber infrastructure company and broadband internet provider said it has raised $80 million…
-
Knowledge Factor Inc., a software-as-a-service company that provides cognitive science-based assessment, training and data analytics…
-
Tilled Inc., a Boulder payment-facilitation technology company, recently completed a $12.5 million investment round, bringing…
